齐拉西酮注射液与氟哌啶醇注射液治疗精神分裂症急性激越症状的对比研究

目的验证甲磺酸齐拉西酮注射液治疗精神分裂症急性激越症状的临床疗效和安全性。方法将64例具有急性激越症状的精神分裂症患者随机分为齐拉西酮组（研究组,32例）和氟哌啶醇组（对照组,32例）,进行开放式临床对照研究,患者入组后即给予臀大肌深部注射齐拉西酮注射液10mg或氟哌定醇注射液5~10mg,6~8小时后可重复使用;甲磺酸齐拉西酮和氟哌啶醇每日总量均不超过30mg,每日注射不超过3次,疗程3天。采用阳性和阴性症状量表（PANSS）、阳性与阴性症状量表兴奋因子（PANSS-EC）、临床总体印象量表（CGI）评分评价疗效;采用药物不良反应量表（TESS）、锥体外系副反应量表（SAS）评价副反应。结果治疗72小时后,齐拉西酮组和氟哌啶醇组的PANSS-EC总分均明显减低,齐拉西酮组PANSS-EC减分率为（47.79±12.94）%,氟哌啶醇组为（47.79±11.49）%,差异无统计学意义（t=0.063,P〉0.05）。齐拉西酮组临床总有效率为46.9%;氟哌啶醇组为40.6%,差异无统计学意义（χ2=0.063,P〉0.05）。齐拉西酮组不良反应发生率为28.1%,氟哌啶醇组65.6%,差异有统计学意义（χ2=9.035,P〉0.05）。结论甲磺酸齐拉西酮治疗精神分裂症的急性激越症状疗效明显,耐受性良好。

Intramuscular ziprasidone versus haloperidol in the treatment of acute agitation in schizophrenia

Objective: To estimate the clinical efficacy and safety of intramuscular mesylate ziprasidone in the treatment of acute agitation in schizophrenia.Methods: Sixty-four schizophrenic patients with acute agitation were divided into the intramuscular mesylate ziprasidone group as the study group(n=32) and the intramuscular haloperidol group as the control group(n=32).The patients were treated with intramuscular mesylate ziprasidone 10mg or intramuscular haloperidol 5-10mg by deep gluteal injection.The medicine ...